3 Big Potential Catalysts for Moderna in 2021
2020 is now hindsight. And what a year it was for Moderna (NASDAQ: MRNA).
The biotech became a household name as it regularly reported encouraging news for its COVID-19 vaccine candidate mRNA-1273. Its share price skyrocketed 434% (and peaked even higher than that). In December, mRNA-1273 became the second COVID-19 vaccine to win U.S. emergency use authorization (EUA).
You might think that the new year could be kind of dull compared to all of that excitement. That won't necessarily be the case, though. Here are three big potential catalysts for Moderna in 2021.
Source Fool.com
